Company news

Monte Rosa Therapeutics, Inc. news in 2025

Monte Rosa Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations

December 16, 2025

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

December 15, 2025

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

November 8, 2025

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

November 6, 2025

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

November 3, 2025

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

October 24, 2025

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

September 15, 2025

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

August 7, 2025

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

July 21, 2025

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

July 3, 2025

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

June 10, 2025

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

May 8, 2025

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

April 28, 2025

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

March 20, 2025

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

March 11, 2025

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

February 24, 2025

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

January 9, 2025

Calls in 2025

Decks in 2025